

Dermoscopy of Non-Melanoma Skin Cancer online series | 4 October – 22 November 2023

This series will overview the clinical and dermoscopic characteristics of non-melanoma skin cancers with the aim of increasing participants' ability to recognise and detect these cancers early.

Registrants will receive seven weekly emails containing a video presented by Dermatology registrars (supervised by Adjunct Associate Professor Amanda Oakley) and other educational material. The series concludes with a 1-hour live online discussion forum on 22 November.

The cost to attend is \$80 (including GST).

This series has been endorsed by RNZCGP for up to 4.5 CME credits for Continuing Professional Development (CPD) purposes and has been approved in the RACS CPD Program for 5 points in Educational Activities.

Find out more Register now

Thank you to our generous sponsors







Missed out on the Dermoscopy Made Easy online course held last Saturday?

Did you miss Adjunct Associate Professor Amanda Oakley's online beginners course <u>Dermoscopy Made Easy</u> held last Saturday, but would have liked to attend? You still have the opportunity to register and receive a link to the recording at the course fee of \$285. Please <u>email us</u> by **Tuesday 26 September** if you are interested.

Our generous sponsors <u>Esteem Healthcare</u>, <u>Heine</u> and <u>Capes Medical</u> have offered some great deals on their dermatoscopes for course participants. Thank you also to MSD for their support of the course.

Find out more about the course

Next MelNet AGM | 28 November 2023

The 2023 MelNet AGM will be held via Zoom from 7.30 – 8.00 pm on Tuesday 28 November 2023.

Members are invited to submit nominations for the Executive Committee in writing to the <u>MelNet Chief Executive</u> no later than 5.00 pm Tuesday 14 November 2023. These should include the nominee's name, a 200-word biography and the signatures of two members.

According to the MelNet rules, the Committee shall comprise at least eight and no more than 15 members, with occupations that span the continuum. Members who will be serving the second year of their two-year term have expertise in general practice, pathology, dermatology, oncology, research and general surgery. Up to nine additional members can be elected to the committee at the AGM. Preference will be given to those with expertise in plastic surgery, primary prevention, nursing and radiology.

Members are also invited to submit remits or other matters to be considered at the AGM to the <u>MelNet Chief</u> <u>Executive</u> no later than 5.00pm Tuesday 14 November 2023.

Keen to attend? Join via this link: <u>https://us02web.zoom.us/j/4453635635</u> or email the <u>MelNet Chief Executive for</u> <u>a calendar invitation</u>.

We look forward to seeing you there.

National Party's election promise to fund three treatments for melanoma

Should they be elected, the National Party pledges an investment of \$280 million over four years to fund 13 cancer treatments, including three treatments for melanoma. The treatments – funded in Australia but not in New Zealand – have been identified by Te Aho o Te Kahu, the Cancer Control Agency to provide "substantial clinical benefit".

The treatments for melanoma are:

- Nivolumab or pembrolizumab for melanoma (adjuvant)
- Dabrafenib with trametinib for melanoma (adjuvant)
- BRAF/MEK inhibitors for melanoma (unresectable)

MelNet encourages all political parties to incorporate policies aimed at reducing the incidence and impact of melanoma and other skin cancers in New Zealand.

Cancer Society 2023-24 Manifesto | Key asks for next Government to take action against cancer

With the launch of their 2023-24 Manifesto, the Cancer Society is calling the next Government to take action against cancer.

They are posing 12 key asks to decision-makers that will help reduce the incidence and impact of cancer in New Zealand. The Manifesto includes a specific ask for a skin cancer prevention and early detection action plan to be developed by mid-2024, with dedicated funding of \$2 million per annum to support its implementation.

Find out more Download manifesto 1-page summary

Get Spotted | Melanoma New Zealand's annual melanoma awareness campaign

16 - 22 October 2023 (or another date that works for you)

Melanoma New Zealand is holding its annual Melanoma Awareness campaign between 16 - 22 October. This is a great opportunity to have fun 'getting spotted' while raising awareness of the importance of early detection and prevention of melanoma. You could dress up or decorate your practice in spots, run a special Melanoma Awareness Campaign skin check offer in support of the cause, or any other support you can offer that helps spread awareness.



Find out more or register your support.

In the media

Eight-week wait for skin cancer test results risking lives

As outlined in our <u>August newsletter</u>, MelNet has been advocating for some time for improved funding and resourcing for pathology services nationwide, but particularly in Auckland. MelNet members and skin cancer specialists have spoken out to media about patient lives being put at risk because of delays getting results back from some laboratories.

Read the article

Ozone season expected to be early this year

NIWA predicts an early and long-lasting ozone hole in the atmosphere this year due to a combination of climate change and last year's volcanic eruption in Tonga. As a result, people should be even more vigilant with sun protection to avoid getting burnt.

Read the article

Upcoming opportunities and events

Goodfellow Unit: Primary prevention of UV radiation | 3 October 2023 7.30 – 8.45 pm

In this webinar hosted by the Goodfellow Unit, Dermatologist Dr Monique Mackenzie will overview:

- Understanding the UV spectrum and its effects on skin
- Protecting skin from UV radiation
- Patients for special consideration.

Find out more Register now



ESMO Congress 2023 | 20 – 24 October 2023 | Madrid, Spain and online

The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives. ESMO 2023 will disseminate the latest cutting-edge data, provide high quality education and unparalleled networking opportunities for oncologists and other stakeholders from all around the world.

Find out more

Other upcoming opportunities and events

October

Dermoscopy of non-melanoma skin cancer online series 4 October - 22 November 2023 Online Find out more

Certificate of Dermoscopy – Online 20 October 2023 Online Find out more

Certificate of Skin Cancer Medicine 20 October 2023

November

38th Annual Meeting & Pre-Conference Programs (SITC 2023) 1 – 5 November 2023 San Diego, USA <u>Find out more</u>

Professional Certificate of Skin Cancer Medicine Professional Certificate of Skin Cancer Surgery 25 November 2023 Perth, Australia Find out more

Online and practical workshop in Christchurch on 18 November Find out more Advanced Skin Surgery Workshop 20 – 23 October 2023 Sydney, Australia Find out more Professional Certificate of Skin Cancer Medicine Professional Certificate of Skin Cancer Surgery 21 October 2023 Melbourne, Australia Find out more Advanced Certificate of Skin Cancer Medicine 22 October 2023 Melbourne, Australia Find out more Professional Diploma of Skin Cancer Surgery 22 October 2023 Melbourne, Australia	Advanced Certificate of Skin Cancer Medicine26 November 2023Perth, AustraliaFind out moreProfessional Diploma of Skin Cancer Surgery26 November 2023Perth, AustraliaFind out moreMelNet AGM28 November 2023OnlineFind out more
Find out more WONCA World Conference 2023 26 – 29 October 2023 Sydney, Australia Find out more ASCO Quality Care Symposium 2023 27 - 28 October 2023 Boston, USA Find out more	

*** For online courses starting any time, please refer to Skin Cancer Education for Primary Care Practitioners ***

Recent MelNet website postings

Below is a selection of recent **news postings** on the MelNet website. Please visit the <u>website</u> to view all the latest news items.

Treating the invisible: Subclinical actinic keratosis detected by imiquimod

Induction of skin cancer by long-term blue light irradiation

SIRT6 pharmacological inhibition delays skin cancer progression in squamous cell carcinoma

Triumphs and challenges of targeting immune checkpoint pathways in melanoma

BRAF status may be important molecular biomarker to guide systemic therapy selection for patients with melanoma brain metastases

Patients unwilling to accept high severe infection risks from oral nicotinamide for reduced risk of non-melanoma skin cancer

Systemic Therapy for Melanoma: ASCO Guideline Update

Necroptosis-related long non-coding RNAs: prognostic model to predict survival of melanoma patients

<u>Need for improved information about harms and benefits of sun exposure to reflect a modern Australian</u> <u>population</u>

Post-treatment cancer survivorship should be established as distinct phase of cancer care





Support our work. Donate to MelNet